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Abstract
We evaluated the preliminary efficacy and feasibility of a next-generation sequencing (NGS)-
based targeted anticancer therapy in refractory solid tumors at a Korean institution. Thirty-six
patients with advanced cancer underwent molecular profiling with NGS with the intent of clini-
cal application of available matched targeted agents. Formalin-fixed paraffin-embedded
(FFPE) tumors were sequenced using the Comprehensive Cancer Panel (CCP) or Founda-
tionOne in the Clinical Laboratory Improvement Amendments-certified laboratory in the USA.
Response evaluations were performed according to RECIST v1.1. Four specimens did not
pass the DNA quality test and 32 specimens were successfully sequenced with CCP (n = 31)
and FoundationOne (n = 1). Of the 32 sequenced patients, 10 (31.3%) were40 years.
Twelve patients (37.5%) had received3 types of prior systemic therapies. Of 24 patients
with actionable mutations, five were given genotype-matched drugs corresponding to action-
able mutations: everolimus to PIK3CAmutation in parotid carcinosarcoma (partial response)
and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to
PDGFRAmutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF
mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2muta-
tion in esophageal adenocarcinoma (progressive disease). Nineteen of 24 patients with
actionable mutations could not undergo targeted therapy based on genomic testing because
of declining performance status (10/24, 41.7%), stable disease with previous treatment (5/24,
20.8%), and lack of access to targeted medication (4/24, 16.7%). NGS-based targeted ther-
apy may be a good option in selected patients with refractory solid tumors. To pursue this
strategy in Korea, lack of access to clinical-grade NGS assays and a limited number of geno-
type-matched targeted medications needs to be addressed and resolved.
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Introduction
In Korea, a total of around 200,000 new solid tumor cases and around 66,000 solid tumor
deaths were reported in 2012 [1]. According to solid tumor types, approximately 30% of
patients had distant metastasis at the time of cancer diagnosis [2]. Systemic chemotherapy is
the standard treatment for these advanced cancer patients. However, many patients have treat-
ment failure after standard therapy. These refractory solid tumor patients have few anti-cancer
treatment options. Many of these patients pay high costs for unproven treatments, such as tra-
ditional medicines, but still do not have an improved survival in advanced solid tumors [2]. In
Korea, the cost of alternative medicine in cancer patients increased from 621 to 1,388 (million
US$, per year) during 2000–2010 [3]. Therefore, development of effective therapeutic strategies
for refractory solid tumors is a huge unmet medical need.
Currently, molecular-based targeted therapy is a standard approach in selected patients
such as non-small cell lung cancer (NSCLC) with EGFRmutations in which a very high
response rate of approximately 75% is observed [4]. More recently, the strategy of matching
targeted drugs to biologically relevant targets using molecular profiling techniques is becoming
better established, although many challenges remain [5,6]. A systematic review of phase II clin-
ical trials in advanced/metastatic NSCLC showed that molecular matching of patients' tumors
to drugs was independently associated with better outcomes as compared with those of unse-
lected patients [7]. Moreover, in the phase I setting, molecular matching was associated with
improved outcomes in multivariate analysis [8].
Despite such advantages, genotype-matched therapy using molecular profiling in advanced
cancer faces various obstacles in many countries. For instance, lack of access to clinical-grade
next-generation sequencing (NGS) testing and targeted medication is the most common bar-
rier. Therefore, we performed a pilot study to evaluate the preliminary efficacy and clinical fea-
sibility of NGS-based targeted anticancer therapy at a Korean institution.
Materials and Methods
Study design
Fig 1 details the study schematic demonstrating the flow of the patients who consented for the
current pilot study of NGS-based targeted anticancer therapy. First, sample quality, such as tis-
sue fragmentation or DNA concentration, was checked using agarose gel or PicoGreenR [9].
After the sample quality check, somatic mutations were identified using FoundationOne by
Foundation Medicine or Ion AmpliSeqTM Comprehensive Cancer Panel (CCP, Life Technol-
ogy) by Macrogen, the Clinical Laboratory Improvement Amendments (CLIA)-certified labo-
ratory, MCL, in Rockville, Maryland [10,11]. In this study, actionable mutation was defined as
a mutation that was either the direct target or a pathway component that could be targeted by
at least one approved or investigational drug. Patients who harbored actionable mutations
were treated using genotype-matched targeted drugs. Approved drugs for the disease or
another disease were given on or off-label, respectively. Drugs in clinical trials were considered
if available. For instance, everolimus is approved for the treatment of renal cell carcinoma by
Korea Food and Drug Administration; however, in this study, everolimus was used in parotid
carcinosarcoma and tracheal squamous cell carcinoma with PIK3CAmutation. In this study,
TP53mutations were not considered actionable mutations as in a similar study [8].
Study objectives
The primary objective of this study was the response rate (RR) as determine by RECIST v1.1
[12] in patients who received genotype-matched therapy. Firstly, radiologists read baseline CT
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scan, MRI or PET CT, and restaging images were read again after targeted therapy. Then,
based on radiologist’ official report, medical oncologists evaluated the tumor response accord-
ing to RECIST 1.1. Secondary objectives included time to progression (TTP) in the same subset
and clinical feasibility of NGS-based targeted anticancer therapy.
Patient eligibility
FromMay 2014 to January 2015, patients with advanced cancer underwent molecular profiling
with NGS with the intent of clinical application of available matched targeted agents at Sever-
ance hospital, Seoul, Korea. Key inclusion criteria were as follows: (1) age 19 years; (2)
refractory solid tumor, which was defined as advanced solid tumor that was refractory to stan-
dard therapy and had no more evidence-based therapies; (3) available tumor tissue; (4) Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2 at enrollment; (5) appropri-
ate organ functions which allow anti-cancer therapy; and (6) signed informed consent. The
study protocol was approved by the Institutional Review Board of Severance Hospital, Yonsei
University College of Medicine, Seoul, Korea.
NGS
Tumor tissue was obtained from biopsy or surgery upon the initial diagnosis of cancer at the
primary or metastasis site, and tumor genomic DNA was extracted from formalin-fixed and
Fig 1. Study scheme. After quality check (QC), samples were sequenced by next generation sequencing
(NGS). Medically fit patients with actionable mutation received matched targeted therapy, but patients who
were not medically fit received chemotherapy or best supportive care (BSC).
doi:10.1371/journal.pone.0154133.g001
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paraffin-embedded (FFPE) tumor tissue. Extracted tumor genomic DNA was sent to Founda-
tion Medicine or Macrogen, the CLIA-certified laboratory in the USA, and library preparation
using FoundationOne or CCP was conducted. CCP is a panel, targeting 409 genes which
includes the exons of tumor suppressor genes and oncogenes frequently mutated [13]. The
panel was designed to be amplification based capture with approximately 16,000 amplicons.
Average amplicon size is 155 base pairs (125–175 base pairs), and it require a total of 40ng of
DNA as a template for each sample. Sequencing was processed by Ion PGMTM system. Foun-
dationOne is a pan-cancer panel, which is designed for 315 cancer related genes and 28 fre-
quently rearranged genes [14].
Analysis platform of NGS data
Our in-house pipeline was applied to analyze CCP data. Sequencing data using CCP was
aligned to the human reference genome build 19 and base calling was performed by Ion
reporter 4.0 versions (Life Technologies). Variants acquired from the CCP panel were filtered
by germline variants acquired from the Korean patients and 1000 genome data including Japa-
nese and Chinese data [15]. We then annotated the variants using ANNOVAR [16], and non-
coding regions and synonymous variants were filtered out. Mutations with low depth, which
indicate50x depths, were filtered out [17]. In addition, mutations with5% variant allele fre-
quency were filtered out [17]. Quality score, which is one parameter of the variant call format
(VCF) using the phred scale, was used to filter out the variants, and Q30 was used for cut-off
value [11,17]. Finally, we reviewed the mutation using the Broad’s Integrative Genomics
Viewer [18]. Variants acquired from the CCP panel were validated by Sanger sequencing in
selected actionable targets. In FoundationOne, a mutation list was provided by the service
provider.
Results
Patient characteristics
A total of 36 patients were enrolled in the pilot study, and samples from 32 patients passed the
quality control test for molecular analysis. Baseline characteristics are presented in Table 1.
The median age was 48.5 years (range, 22–72 years), and 10 (31.3%) patients were40 years
old. Eleven NSCLC (34.4%) patients (10 adenocarcinomas and one neuroendocrine carci-
noma) and four (12.4%) esophageal cancer patients were enrolled, and patients with various
tumor types were enrolled in small numbers. Types of previous systemic therapy ranged from
1 to 5, and patients with3 previous chemotherapy histories were 12 (37.5%).
NGS test results
To identify somatic mutations, we performed the CCP platform on 31 samples and Foundatio-
nOne on one sample to a median depth of 823x and 562x, respectively. We identified 44 action-
able mutations which were missense or truncation mutations. The list of actionable mutations
in all patients is described in Table 2. Twenty-four (75%) of 32 patients had1 actionable
mutations; 11 (34.4%), 8 (25%), 3 (9.4%), and two (6.3%) patients had 1, 2, 3, and 4 actionable
mutations, respectively. The frequency of each actionable mutation is shown in Fig 2, and the
most common mutations were EGFR, ERBB2, ROS1, and PIK3CAmutations (3/32, 9.4%).
Outcome of genotype-matched therapy
Of 24 patients with actionable mutations, five received genotype-matched targeted therapy
according to potential biological impact of mutations and availability of drugs in Korea, but 19
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could not begin targeted therapy based on genomic tests because of declining performance sta-
tus (10/24, 41.7%), stable disease with previous treatment (5/24, 20.8%), and lack of access to
targeted medication (4/24, 16.7%). In particular, six of 11 NSCLC patients harbored actionable
mutations but none were given genotype-matched therapy.
Of five patients who received genotype-matched targeted therapy, two showed partial
response (PR), one showed stable disease (SD; −21%), but two had progressive disease (PD)
just after initiation of matched therapy (Table 3). Everolimus was administered to PI3K/mTOR
pathway genes-mutated patients. A parotid carcinosarcoma patient and tracheal squamous cell
carcinoma patient who both had PIK3CAmutation (H1047R) showed PR and SD (−21%) to
everolimus, respectively. The PIK3CAmutation (H1047R) in the parotid carcinoma patient
was validated with Sanger sequencing. Before everolimus therapy, both patients received cis-
platin based concurrent chemoradiotherapy, and tracheal squamous cell carcinoma patient
additionally received gemcitabine and carboplatin chemotherapy, but they became refractory
status. Two patients with PDGFRA or BRAFmutation received sorafenib which is known to
target PDGFR and RAF. The external auditory canal adenocarcinoma patient, who had a
PDGFRAmutation (L710F), achieved PR with sorafenib (Fig 3). Before sorafenib therapy, the
patient received several lines of chemotherapy including cisplatin based CCRT, 5-fluorouracil/
cisplatin, etoposide/cisplatin, and KX2-391/paclitaxel chemotherapy, but finally progressed to
all regimens. However, the microcystic adnexal carcinoma of scalp patient with a BRAF
Table 1. Patient characteristics at time whenmutation profiling was performed.
Characteristic Number (%)
Age, years Median (Range) 48.5 (22~72)
Sex
Male 19 (59.4%)
Female 13 (40.6%)
ECOG performance status
1 17 (53.1%)
2 14 (43.8%)
3 1 (3.1%)
Cancer type
Non-small cell lung cancer 11 (34.4%)
Esophageal cancer 4 (12.4%)
Adenoid cystic carcinoma 2 (6.3%)
Thymic carcinoma 2 (6.3%)
Mesothelioma 2 (6.3%)
Squamous cell cancer of head and neck 2 (6.3%)
Othersa 9 (28.1%)
Lines of previous CTx
1 13 (40.6%)
2 7 (21.9%)
3 3 (9.4%)
4 6 (18.8%)
5 3 (9.4%)
ECOG, Eastern Cooperation Oncology Group; CTx, chemotherapy
aOthers includes 1 external auditory canal adenocarcinoma, 1 breast cancer, 1 parotid carcinosarcoma, 1
endometrial clear cell carcinoma, 1 colon cancer, 1 microcystic adexal cancer of scalp, 1 non-clear renal
cell cancer, 1 seminoma, 1 tracheal squamous cell carcinoma.
doi:10.1371/journal.pone.0154133.t001
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Table 2. List of actionable mutations in all patients.
No Cancer type Chr Loci Ref/Alt Gene Mutation type Platform
1 Adenocarcinoma, lung 22 30079008 G/T NF2 p.Ser568Ile CCP
2 Breast cancer 17 29684104 T/C NF1 p.Val415Ala CCP
3 Adenocarcinoma, lung 7 55242463 AAGGAATTAAGAG/A EGFR Exon 19 del CCP
3 Adenocarcinoma, lung 7 106508614 C/T PIK3CG p.Thr203Met CCP
3 Adenocarcinoma, lung 9 98242853 C/T PTCH1 p.Arg104Gln CCP
4 ADC, external auditory canal 4 55144656 G/C PDGFRA p.Leu710Phe CCP
4 ADC, external auditory canal 4 153244124 G/C FBXW7 p.Ser598* CCP
5 Pericardial mesothelioma 17 17129556 C/A FLCN p.Gln110His CCP
7 ESCC 10 43619231 A/G RET p.Arg972Gly CCP
7 ESCC 6 166836748 G/A RPS6KA2 p.Pro491Leu CCP
8 Carcinosarcoma, parotid 3 178952085 A/G PIK3CA p.His1047Arg CCP
8 Carcinosarcoma, parotid 6 117683803 A/C ROS1 p.Leu1115Arg CCP
8 Carcinosarcoma, parotid 12 56495022 C/T ERBB3 p.Arg247Cys CCP
9 Trachea SCC 3 178952085 A/G PIK3CA p.His1047Arg CCP
9 Trachea SCC 15 66737039 C/T MAP2K1 p.His101Tyr CCP
10 Colon cancer 1 162731077 G/A DDR2 p.Ser311Asn CCP
11 Renal cell ca, non-clear cell 6 117686800 G/A ROS1 p.Pro973Ser CCP
12 Adenoid cystic carcinoma 17 37873715 C/A ERBB2 p.Pro627His CCP
13 Adenocarcinoma, lung 7 55242463 AAGGAATTAAGAG/A EGFR Exon 19 del CCP
13 Adenocarcinoma, lung 9 98231106 G/A PTCH1 p.Pro725Leu CCP
14 ACC, external auditory canal 12 25398284 CC/AC KRAS p.Gly12Val CCP
14 ACC, external auditory canal 2 212293159 G/C ERBB4 p.Thr898Ser CCP
14 ACC, external auditory canal 7 128850877 A/T SMO p.Lys575Met CCP
15 Oropharyx cancer 3 178916946 G/C PIK3CA p.Lys111Asn CCP
16 Pleural mesothelioma 22 30038197 A/T NF2 p.Lys124* CCP
16 Pleural mesothelioma 5 149509521 C/T PDGFRB p.Glu130Lys CCP
17 NSCLC, large cell neuroendocrine 8 38283724 C/A FGFR1 p.Val132Leu CCP
17 NSCLC, large cell neuroendocrine 16 2114297 A/C TSC2 p.Ile490Leu CCP
17 NSCLC, large cell neuroendocrine 17 17124799 C/G FLCN p.Gly308Ala CCP
17 NSCLC, large cell neuroendocrine 6 117641053 C/A ROS1 p.Gly1973Val CCP
18 Seminoma 13 28623881 G/A FLT3 p.Pro258Leu CCP
22 ESCC 4 55961059 G/A KDR p.Arg961Trp CCP
24 Microcytic adenxal carcinoma 7 140453154 T/C BRAF p.Asp22Gly CCP
26 Adenocarcinoma, lung 11 108139269 G/A ATM p.Arg183Gln CCP
28 EADC 1 204419139 G/C PIK3C2B p.Cys691Trp CCP
28 EADC 17 37873715 C/A ERBB2 p.Pro597His CCP
29 Adenocarcinoma, lung 17 37873715 C/A ERBB2 p.Pro627His CCP
29 Adenocarcinoma, lung 5 149497184 G/A PDGFRB p.Ala1045Val CCP
30 thymic carcinoma 16 2121538 G/T TSC2 p.Ala623Ser CCP
30 thymic carcinoma 9 135779171 C/T TSC1 p.Arg692Gln CCP
32 Adenocarcinoma, lung EGFR L747_P753insS Foundation
32 Adenocarcinoma, lung KDR Ampliﬁcation Foundation
32 Adenocarcinoma, lung KIT Ampliﬁcation Foundation
32 Adenocarcinoma, lung PDGFRA Ampliﬁcation Foundation
No, number; Chr, chromosome; Ref, reference; Alt, alteration; ADC, adenocarcinoma; ESCC, esophageal squamous cell carcinoma; SCC, squamous cell
carcinoma; ACC, adenoid cystic carcinoma; NSCLC, non-small cell lung carcinoma; EADC, esophageal adenocarcinoma; CCP, comprehensive cancer
panel.
doi:10.1371/journal.pone.0154133.t002
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mutation (D22G) showed PD to sorafenib within 1 month. Lastly, esophageal adenocarcinoma
patient with ERBB2mutation (P597H) received afatinib, which targets ERBB2, but showed PD
within 1 month. Previous treatment history of patients with matched therapy was described in
S1 Table. TTP in five patients who received genotype-matched therapy was 3.7 months (range,
0.7–6.7).
Discussion
For patients with refractory solid tumor, genome-based basket [19], umbrella [20], or phase I
clinical trials [8] are drawing attentions. The basket trial allows patients with several tumor
types with the same actionable target to be enrolled in trial. The other approach is umbrella
Fig 2. Frequency of each actionable mutation.
doi:10.1371/journal.pone.0154133.g002
Table 3. Outcomes of matched therapy.
Patient
number
Age ECOG
status
Tumor type Targeted
mutation
Other mutation Drug Best
response
TTP
(months)
1 63 2 External auditory canal
adenocarcinoma
PDGFRA
(L710F)
FBXW7 Sorafenib PR (-68%) 3.7
2 37 1 Parotid carcinosarcoma PIK3CA
(H1047R)
ROS1, ERBB3,
TP53
Everolimus PR (-30%) 5.8
3 48 1 Tracheal squamous cell
carcinoma
PIK3CA
(H1047R)
MAP2K1 Everolimus SD (-21%) 6.7
4 49 3 Microcystic adnexal carcinoma
of scalp
BRAF (D22G) None Sorafenib PD 0.7
5 63 2 Esophagus adenocarcinoma ERBB2
(P597H)
PIK3C2B, TP53 Afatinib PD 0.9
ECOG, Eastern Cooperation Oncology Group; TTP, time to progression; PR, partial response; SD, stable disease; PD, progressive disease.
doi:10.1371/journal.pone.0154133.t003
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trial, which is designed to test the impact of different drugs on different mutations in a single
type of cancer, on the basis of molecular profile. However, these studies are only accessible in a
limited number of countries. In a Korean institution, we evaluated the preliminary efficacy and
clinical feasibility of NGS-based anticancer therapy in refractory solid tumors.
In this study, NGS-based genotype-matched therapy showed efficacy in patients with refrac-
tory solid tumors for which we did not have standard therapeutic options, although only small
number of patients received genotype-matched therapy. Of five patients with refractory solid
tumor who received genotype-matched therapy in this study, significant tumor reduction was
seen in three patients (60%; two PRs, one decreasing SD by −21%). In a phase I Program at
MD Anderson Cancer Center in the similar clinical setting, the response rate (RR) was 25%
[8], whereas RR was only 4% in the patients with non-matched therapy [7]. However, a
recently published SHIVA trial [21], which was a randomized, phase II trial to compare
genome-based molecularly targeted therapy versus conventional therapy for advanced cancer,
failed to show any improvement in survival or responses with genome-based targeted thera-
pies. However, weakness of SHIVA trial can be found [22]: 1) patients with several co-existing
molecular alterations are unlikely to respond to a single targeted therapy [23], 2) hormone
monotherapy in heavily treated patients is unlikely to bring clinical response [24], 3) some tar-
geted agents were incorrectly matched to molecular alterations [25], 4) treatment in the control
group was offered at the discretion of physicians which may lead biases. Furthermore, two
meta-analyses in 70,000 patients reported that trials with a personalized strategy led to a higher
proportion of patients achieving responses and longer progression-free and overall survival
than trials with unselected patients [26,27]. Therefore, it is hard to generally accept the conclu-
sions of the SHIVA trial that precision therapy is disappointing and that the use of targeted
drugs off-label should be discouraged. Taken together, although the current study is a small
pilot trial in Korea, we suggest that NGS-based genotype-matched therapeutic approaches may
Fig 3. Tumor reduction in external auditory canal adenocarcinoma patient with PDGFRAmutation
(L710F) after sorafenib treatment. (A and B) multiple lung metastases disappeared and (C and D) huge
anterior chest wall mass remarkably shrank after 4 weeks of sorafenib treatment.
doi:10.1371/journal.pone.0154133.g003
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be feasibly tested in larger trials and also may provide reasonable treatment options to refrac-
tory solid tumor patients in Korea in the future.
Two patients whose tumors responded to everolimus (one PR, one SD with 21% decrement)
had the PIK3CAmutation (H1047R), which is already known to be a predictive marker for
PI3K/AKT/mTOR pathway inhibitors [28]. An external auditory canal adenocarcinoma patient
who showed PR to sorafenib harbored the PDGFRAmutation (L710F). The PDGFRAmutation
is observed in approximately 7% of gastrointestinal stromal tumor, and 80% of the PDGFRA
mutations are found in exon 18, which is located in the tyrosine kinase domain [29]. Our
patient’s PDGFRAmutation (L710F) was located in the tyrosine kinase domain but was a
novel mutation. A prediction of the functional effect of this novel mutation was performed by
PolyPhen-2 [30] and possibly damaging was expected. Previous studies showed that sorafenib
could inhibit the proliferation of cell lines or patient’s tumor with PDGFRAmutation [31,32].
The patient with a microcystic adnexal carcinoma of scalp who had a BRAFmutation (D22G)
showed PD to sorafenib. That may be explained from the fact that the patient had a non-
V600E BRAFmutation, which was not located in the kinase domain [33]. In addition, the
patient’s poor general condition partly accounted for early PD. An esophageal adenocarcinoma
patient with an ERBB2mutation (P597H) also did not benefit from afatinib. Although the
mutation locus was in the extracellular domain and could be related to ERBB2 activation
[34,35], the patient also had a PIK3C2Bmutation, which may cause PI3K pathway activation
and subsequent resistance to afatinib.
In this study, we found several obstacles in terms of the clinical feasibility in performing
NGS-based targeted anticancer therapy. First, there were no clinical-grade NGS assays avail-
able in Korea. Thus, we had to send samples for identifying patient’s mutation profile to a
CLIA-certified laboratory in the USA. This made turn-around time about 4 weeks, which was
too long for advanced cancer patients whose remaining survival time was not long. Clinical-
grade NGS assays should be developed soon in Korea. Simpler hotspot cancer gene panels used
in clinical practice may be sufficient to detect actionable mutations. The cost of NGS is also a
challenging issue. It is currently not covered by either national health or private insurance in
Korea. Therefore, in the near future, discussion should be started on the coverage of NGS by
national health insurance or at least by private insurance once to twice per each cancer patient.
Second, limited access to targeted medications was the most common reason that patients
could not be treated. Genome-based basket or phase I trials, which can be offered to refractory
solid tumor patients, are not enough in Korea. Thus, our patients were administered genotype-
matched therapy off-label. Therefore, Korean medical oncologists should make vigorous efforts
to quickly launch genome-based trials for refractory solid tumor patients.
This study has a few limitations. A very small number of patients were enrolled for evaluat-
ing the efficacy of genome-based matched therapy. We need more robust evidence for better
clinical outcomes with NGS-based targeted therapy to recommend this approach in clinical
practice. Second, paired normal samples were not sequenced for somatic mutation calling. This
may be related to false-positive findings of somatic mutations [36]. To fix this problem, we
used germline variants acquired from Korean patients and 1000 genome data to filter out false-
positive findings in somatic mutations. Third, the novel mutation as an actionable target lacks
evidence of functional changes in the protein, although the novel mutation is a missense muta-
tion. It is difficult to predict the functional consequence of the novel mutation. Only functional
in-vitro and in-vivo studies can identify the role of that mutation. As expected, the survival
time of refractory solid tumor patients was short, and we did not have time to validate func-
tional change of somatic mutations before we administered drugs to patients. However, some
of actionable mutations are currently under functional validation.
Pilot Study of NGS-Based Target Therapy
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In conclusion, NGS-based targeted therapy may be a good option in selected patients with
refractory solid tumors. To pursue this strategy in Korea, lack of access to clinical-grade NGS
assay and limited number of genotype-matched targeted medications needs to be addressed
and resolved.
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